Chlamydia and HIV Co-infection: Synergistic Risks, Transmission Dynamics, and Management

Yes, chlamydia and HIV frequently co-occur due to shared transmission routes (sexual) and biological synergy.

Bidirectional Risk Amplification

Direction	Mechanism	Magnitude
Chlamydia → ↑ HIV acquisition	Genital inflammation ↑ CD4+ target cells; mucosal barrier disruption; ↑ viral shedding in HIV+ partner.	2–5× higher HIV acquisition risk.
HIV → ↑ Chlamydia susceptibility/persistence	CD4+ depletion → impaired mucosal immunity; altered genital microbiome; ↓ clearance.	Higher prevalence, recurrent infection, LGV risk.
Co-infection → ↑ HIV transmission	Chlamydia ↑ HIV RNA in genital secretions (↑ viral load) → ↑ infectivity.	Significant public health driver.

Clinical Implications

• Screen all HIV+ patients for chlamydia at entry to care, annually, and with new partners (NAAT: urine, swabs).
• Screen all chlamydia patients for HIV (opt-out testing).
• Treat chlamydia promptly: Doxycycline 100 mg BID ×7d (preferred) or azithromycin 1g single dose. Same regimens for HIV+ (check interactions: doxycycline OK; azithromycin with some ARTs).
• Expedited Partner Therapy (EPT) for chlamydia reduces reinfection.
• ART adherence suppresses HIV viral load → reduces transmission and may improve chlamydia clearance.

Special Considerations

• LGV (Lymphogranuloma venereum): Caused by C. trachomatis L1–L3. Rising in MSM with HIV. Proctocolitis, fistulas. Treat: doxycycline 100 mg BID ×21d.
• Rectal/pharyngeal chlamydia: Common in MSM; often asymptomatic. Test all exposed sites.
• Pregnancy: Azithromycin preferred; test for HIV/syphilis/hepatitis concurrently.

Public Health Impact

Integrated STI/HIV services (colocated testing, same-day treatment, PrEP linkage) are cost-effective and reduce population-level transmission. Treat chlamydia as an HIV prevention intervention.